Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCB1381 in Healthy Participants and Atopic Dermatitis
NCT05277571Phase 2Completed
- Sponsor
- UCB
- Start
- Mar 2022
- Primary completion
- Jul 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of donzakimig in atopic dermatitis (AD), sponsored by UCB. Started Mar 2022; status: completed.
02
Drugs
donzakimig
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05277571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05277571.